Insomnia, anxiety, headaches, worsening migraines, palpitations, heavy or unpredictable bleeding, vaginal dryness, urinary symptoms, joint pain, low mood and brain fog can all turn up in perimenopause while periods are still happening. The first job in pharmacy and primary care is pattern recognition, not dismissal.
Why the diagnosis is often missed
Perimenopause is the stage leading up to menopause, when ovarian function becomes more erratic and hormone levels begin to fluctuate. That fluctuation can drive symptoms long before periods stop completely, which is where misdiagnosis begins: anxiety may be treated as a stand-alone mental health problem, headaches as a migraine flare, heavy bleeding as a gynaecology issue, and poor sleep as a lifestyle problem.
Symptoms can affect relationships, social life, family life and work, and ethnic background can affect how symptoms present, how severe they are and how long they last. The joint position statement from the British Menopause Society, the Royal College of Obstetricians and Gynaecologists and the Society for Endocrinology puts the share of women who experience menopausal symptoms at more than 75%.
What the symptom pattern looks like
The common mistake is to expect perimenopause to announce itself only through vasomotor symptoms. Hot flushes, disturbed sleep, mood changes, brain fog, joint aches and skin changes are all part of the picture, and the Menopause Charity describes brain fog as a very common symptom that can feel like “cotton wool”. Forgetfulness and difficulty concentrating can be the symptom that pushes someone to seek help, not a hot flush.
The same applies to bleeding and migraine. Heavy or unpredictable bleeding can be a major feature of the transition, and worsening migraines or new headaches can sit alongside anxiety, poor sleep and palpitations. For pharmacists, that cluster should trigger a menopause conversation rather than a series of one-off symptom treatments.
What to rule out before calling it perimenopause
A sensible assessment does not stop at symptom recognition. The core differentials include thyroid disease, pregnancy, medication side effects, anaemia and depression, all of which can overlap with perimenopausal symptoms. Abnormal bleeding, persistent low mood, marked fatigue or a sudden change in symptom pattern should not be waved away as “just hormones”.
NICE guideline NG23 states that menopause care should be individualised, and NICE’s overview page lists the guideline as last reviewed on 15 April 2026. NICE also amended its advice on when to seek help for vaginal bleeding while taking systemic HRT.
What can be managed first in pharmacy
Not every woman needs medication at the first contact. Some will benefit from reassurance that the symptom cluster fits perimenopause, especially if the main issues are sleep disruption, irritability or early mood changes. Practical advice on sleep and exercise is part of that first-line support, and it is often the difference between someone coping for a few weeks and someone spiralling into repeated appointments.
Pharmacy is also the place to steer people away from treating each symptom in isolation. If a woman presents with brain fog, anxiety and poor sleep, the right response is not simply a sleep aid or a supplement aisle recommendation. The pattern itself may be the clue that hormonal transition is driving the problem.
When treatment needs to be individualised
Perimenopause management is symptom-led, not one-size-fits-all. Some women need treatment focused on vasomotor symptoms or mood; others need investigation for abnormal bleeding; others need contraception advice as well as symptom control. Age, risk factors, symptom burden and reproductive goals all shape the plan, which is why shared decision-making is central rather than optional.
Where systemic oestrogen is used in a woman who has a uterus, progestogen protection is generally required. Some women may also do better with non-oral options depending on their risk profile and symptom pattern. Do not assume one hormonal approach suits every patient, because treatment choice changes depending on whether the main issue is symptoms, bleeding, or contraception.
The Menopause Charity’s summary of the 2024 NICE guideline lists the update as last updated in November 2024 and planned for review in November 2027.
Why pharmacists matter now
Community pharmacists often see women before a GP appointment is booked, especially when they are looking for over-the-counter help, supplements or quick advice. A systematic review of community pharmacy interventions found pharmacy-based support for peri- and post-menopausal health is an emerging area of practice. The British Menopause Pharmacy Society has also been established to build a confident, capable and connected pharmacy workforce for menopause care.
Menopausal women are the fastest-growing demographic in the workplace, and NHS England’s menopause-in-the-workplace material includes the Faculty of Occupational Medicine’s estimate that almost 8 out of 10 menopausal women are in work.
A Westminster Hall debate on support for people experiencing menopausal symptoms was scheduled for Wednesday 9 June 2021 from 4:50 to 5:50pm.